Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study

This article has no abstract
Epistemonikos ID: 3be5a79a8c49d6fd360d9b02f4756f8fb4894d15
First added on: Feb 08, 2025